ImmunoGen shares tank (again) after the FDA nixes a shot at an OK for its armed antibody in wake of a failed PhIII
ImmunoGen $IMGN just compounded its woes with their lead drug.
Two months after acknowledging that their antibody-drug conjugate mirvetuximab soravtansine failed a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
